- Home
- ADC vs ROIV Comparison
ADC vs ROIV Comparison
Compare ADC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADC
- ROIV
- Stock Information
- Founded
- ADC 1971
- ROIV 2014
- Country
- ADC United States
- ROIV United Kingdom
- Employees
- ADC N/A
- ROIV N/A
- Industry
- ADC Real Estate Investment Trusts
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- ADC Real Estate
- ROIV Health Care
- Exchange
- ADC Nasdaq
- ROIV Nasdaq
- Market Cap
- ADC 8.0B
- ROIV 8.6B
- IPO Year
- ADC 1994
- ROIV N/A
- Fundamental
- Price
- ADC $75.23
- ROIV $17.86
- Analyst Decision
- ADC Buy
- ROIV Strong Buy
- Analyst Count
- ADC 12
- ROIV 8
- Target Price
- ADC $81.45
- ROIV $19.94
- AVG Volume (30 Days)
- ADC 1.1M
- ROIV 7.8M
- Earning Date
- ADC 10-21-2025
- ROIV 11-11-2025
- Dividend Yield
- ADC 4.10%
- ROIV N/A
- EPS Growth
- ADC N/A
- ROIV N/A
- EPS
- ADC 1.68
- ROIV N/A
- Revenue
- ADC $659,753,000.00
- ROIV $23,233,000.00
- Revenue This Year
- ADC $15.42
- ROIV N/A
- Revenue Next Year
- ADC $10.73
- ROIV $200.91
- P/E Ratio
- ADC $44.58
- ROIV N/A
- Revenue Growth
- ADC 13.16
- ROIV N/A
- 52 Week Low
- ADC $67.58
- ROIV $8.73
- 52 Week High
- ADC $79.65
- ROIV $18.06
- Technical
- Relative Strength Index (RSI)
- ADC 67.39
- ROIV 85.43
- Support Level
- ADC $69.76
- ROIV $16.89
- Resistance Level
- ADC $75.99
- ROIV $18.06
- Average True Range (ATR)
- ADC 1.06
- ROIV 0.50
- MACD
- ADC 0.56
- ROIV 0.08
- Stochastic Oscillator
- ADC 87.80
- ROIV 92.70
About ADC Agree Realty Corporation
Agree Realty Corporation operates as a fully integrated real estate investment trust mainly focused on the ownership, acquisition, development and management of retail properties net leased to industry-tenants. The Company is mainly in the business of acquiring, developing and managing retail real estate. Some of its properties in the portfolio include Walmart, 7-Eleven, Wawa, Gerber Collision and others.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.